Use with caution in patients with inflammatory bowel disease.
- TRADE NAME: Cosentyx (Novartis)
- INDICATIONS: Moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis
- CLASS: Antipsoriatic agent, Biologic, Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor, Monoclonal antibody
- HALF-LIFE: 22–31 days
- FDA APPROVAL DATE: 01/21/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines
- See adverse reactions attributed to class:
Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see two reviews of secukinumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/06/2025
